⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVO News
Novo-Nordisk A/S
Sunlight.com Survey: 1 in 7 Americans Plan To Use GLP-1s in 2026
prnewswire.com
NVO
LLY
Clinic Secret Unveiled: How This GLP-1 Weight Loss Platform Enables At-Home Access to Ozempic, Semaglutide & Tirzepatide - Clinic Secret
globenewswire.com
NVO
Rise of Direct-to-Patient GLP-1 Sales Shakes Up Care Models, HCPs Split on Pharma’s Expanding Role
businesswire.com
LLY
NVO
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management USA - English USA - English
prnewswire.com
NVO
Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management USA - English USA - English
prnewswire.com
NVO
Drug Delivery Devices Market Set to Exceed US$ 450.7 Billion by 2035 as Biologic Revenue Surges Drive Urgent Expansion of Device Manufacturing Capacity Says Astute Analytica
globenewswire.com
LLY
NVO
BDX
WST
STZ
DrMedHealth.com Launches Nationwide GLP-1 Medical Weight Loss Program with Board-Certified Physicians
accessnewswire.com
LLY
NVO
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
globenewswire.com
VRTX
NVO
CRSP
Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing
businesswire.com
LLY
NVO
Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss
globenewswire.com
NVO